Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1269
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1021–1032 of 1,269 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer

NCT05387915
Site status not listed — check the official record
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal HPV-Positive Squamous Cell Carcinoma
Interventions
Radiation Therapy
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer

NCT02504697
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Biosamples from airway and blood
Other
Lead sponsor
Boston University
Other
Eligibility
50 Years to 79 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Not applicable Interventional

Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis)

NCT04996173
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Spray cryotherapy, Ballon Dilation, Radial Incision
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Jackson, Mississippi • Nashville, Tennessee • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Phase 2 Interventional Results available

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

NCT01898494
Site status not listed — check the official record
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin
Procedure · Radiation · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
58
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Phase 2 Interventional

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

NCT04947319
Site status not listed — check the official record
View directory record Official record
Conditions
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Interventions
Tirabrutinib
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Autonomic Determinants of POTS - Pilot1

NCT04050410
Site status not listed — check the official record
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Moxonidine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Early Phase 1 Interventional

Autonomic Determinants of POTS - Pilot 2

NCT04140721
Site status not listed — check the official record
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Placebo oral tablet, Moxonidine Pill
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Recruiting Not applicable Interventional

Mobile Health Intervention to Improve Exercise in Pediatric PH

NCT06549452
Status at this site: Recruiting
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
mHealth Intervention, Usual Care
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Phase 3 Interventional

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

NCT06239480
Site status not listed — check the official record
View directory record Official record
Conditions
Microcystic Lymphatic Malformation
Interventions
QTORIN 3.9% Rapamycin Anhydrous Gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Irvine, California • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting No phase listed Observational

Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage

NCT00593268
Site status not listed — check the official record
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Phase 2 Interventional

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

NCT03286530
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation
Interventions
Ruxolitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 9, 2026, 2:10 PM EST
Active, not recruiting Not applicable Interventional

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

NCT06638398
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review
Procedure · Device · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 9, 2026, 2:10 PM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.